International Study Finds New Drugs Combination to Cut Deaths from Diabetes

The largest-ever study of treatments for diabetes has shown that a combination of two blood pressure-lowering drugs reduces the risk of death, heart attack and kidney disease in diabetes sufferers. The "Action in diabetes and vascular disease" (ADVANCE) project involves 20 countries from around the world, 12 of them from the EU. The results were presented at the European Society of Cardiology Congress in Vienna, Austria, on 3 September.

A total of 11,140 patients took part in trials, which lasted over four years. Half of the participants received a fixed combination of two blood pressure-lowering drugs (perindopril and indapamide) in a single tablet, daily. The other half received a matching inactive placebo.

"These results represent an important step forward in health care for millions of people with diabetes worldwide," said Professor Stephen MacMahon from the George Institute for International Health in Australia. "This treatment reduced the likelihood of dying from the complications of diabetes by almost one-fifth, with virtually no side-effects."

Type 2 diabetes is the most common form of diabetes, mostly affecting adults. Sufferers are known to be at a high risk of developing major health problems earlier in life than those without diabetes. In particular, sufferers are more likely to experience a heart attack, stroke, blindness, kidney failure and leg ulcers that can lead to amputation.

The study participants were already receiving most of the standard treatments for diabetes, including other drugs to lower blood pressure. But the precise combination used in this study resulted in a 14% reduction in the risk of death, and an 18% reduction in the risk of death from cardiovascular disease. "In absolute terms, one death would be avoided for every 79 patients treated with the fixed combination of perindopril and indapamide for five years," said Study Director Dr Anushka Patel, also from the George Institute.

Currently around 250 million people worldwide have diabetes, and this number is growing rapidly. The majority of these people will either die or become disabled by the complications inherent in their condition.

For further information, please visit:
http://www.advance-trial.com/static/html/prehome/prehome.asp

Copyright ©European Communities, 2007
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.

Most Popular Now

AstraZeneca amends collaboration with Ironwood for…

AstraZeneca has amended its collaboration agreement with Ironwood Pharmaceuticals, Inc. (Ironwood) in China mainland, China Hong Kong and China Macau for Linzess (linaclo...

Cause of antibiotic resistance identified

Scientists have confirmed for the first time that bacteria can change form to avoid being detected by antibiotics in the human body. Studying samples from elderly patient...

Bayer, Brigham and Women’s Hospital, and Massachus…

Bayer and Partners HealthCare's founding members Brigham and Women's Hospital (BWH) and Massachusetts General Hospital (MGH) today announced the launch of a joint lab to ...

FDA grants Fast Track designation for Farxiga in h…

AstraZeneca announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to reduce the risk ...

Amgen announces positive results from two Phase 3 …

Amgen (NASDAQ:AMGN) today announced that the results of a prespecified interim analysis of an open-label, randomized, controlled global multicenter Phase 3 trial (2012021...

Brilinta monotherapy in high-bleeding risk patient…

New data from TWILIGHT, a Phase IV independent trial (funded by AstraZeneca), showed that in patients at high-bleeding risk who underwent PCI and completed 3 months of du...

AstraZeneca divests rights for Losec to Cheplaphar…

AstraZeneca has agreed to sell the global commercial rights, excluding China, Japan, the US and Mexico, for Losec (omeprazole) and associated brands to Cheplapharm Arznei...

Educational campaign helps teens and their caregiv…

Teenagers face many challenges, and growing up with a chronic skin disease called atopic dermatitis (AD) can impact the ups and downs and transitions to young adulthood. ...

Gene-targeted cancer drugs, slow release overcome …

Biomedical engineers at Duke University have developed a method to address failures in a promising anti-cancer drug, bringing together tools from genome engineering, prot...

Ian Read to retire as Executive Chairman of Pfizer…

Following its regularly scheduled meeting, the Board of Directors of Pfizer Inc. (NYSE:PFE) today announced that Executive Chairman of the Board Ian C. Read has chosen to...

Novartis and Microsoft announce collaboration to t…

Novartis announced an important step in reimagining medicine by founding the Novartis AI innovation lab and by selecting Microsoft as its strategic AI and data-science pa...

Study points to new drug target in fight against c…

Researchers have identified a potential new drug target in the fight against cancer. In a study this week in the Proceedings of the National Academy of Sciences, an inter...